Literature DB >> 26397065

A Review of Current Animal Models for the Study of Cervical Dysplasia and Cervical Carcinoma.

Luke I Larmour1, Tom W Jobling, Caroline E Gargett.   

Abstract

Cancer research has long relied on animal models for the study of disease mechanisms and new therapeutics. Future cancer treatments are likely to rely heavily on patient-derived xenograft models to develop novel treatments and tailor regimens to individual patient needs. However, specific models for cervical cancer and cervical dysplasia are limited. Only 3 models have been described in the published literature. A transgenic model for cervical cancer has allowed for the study of the differential contributions of the human papillomavirus 16 proteins E6 and E7 during oncogenesis. This model has also shown dysplasia development, although this has received little attention. A patient-derived tumor xenograft model where cervical cancer tissue is transplanted to the subcutaneous and orthotopic sites has been described. Here we review the reported transgenic and xenograft models, their strengths and limitations, and highlight the potential for the development of improved models to study cervical neoplasia.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26397065     DOI: 10.1097/IGC.0000000000000525

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  8 in total

1.  Development of a goat model for evaluation of withaferin A: Cervical implants for the treatment of cervical intraepithelial neoplasia.

Authors:  Leslie C Sherwood; Farrukh Aqil; Manicka V Vadhanam; Jeyaprakash Jeyabalan; Radha Munagala; David Hoetker; Sanjay Srivastava; Inder P Singh; Scott Cambron; Martin O'Toole; Wendy Spencer; Lynn P Parker; Ramesh C Gupta
Journal:  Exp Mol Pathol       Date:  2017-11-21       Impact factor: 3.362

Review 2.  Preclinical mouse solid tumour models: status quo, challenges and perspectives.

Authors:  Nicolas Gengenbacher; Mahak Singhal; Hellmut G Augustin
Journal:  Nat Rev Cancer       Date:  2017-10-27       Impact factor: 60.716

3.  Influence of the estrus cycle of the mouse on the disposition of SHetA2 after vaginal administration.

Authors:  Sanjida Mahjabeen; Manolya Kukut Hatipoglu; Doris M Benbrook; Stanley D Kosanke; David Garcia-Contreras; Lucila Garcia-Contreras
Journal:  Eur J Pharm Biopharm       Date:  2018-07-04       Impact factor: 5.571

4.  Localized Delivery of Cisplatin to Cervical Cancer Improves Its Therapeutic Efficacy and Minimizes Its Side Effect Profile.

Authors:  Cinzia Federico; Jennifer Sun; Barbara Muz; Kinan Alhallak; Pippa F Cosper; Naoshad Muhammad; Amanda Jeske; Amanda Hinger; Stephanie Markovina; Perry Grigsby; Julie K Schwarz; Abdel Kareem Azab
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-11-27       Impact factor: 7.038

5.  Establishment of an Immortalized Skin Keratinocyte Cell Line Derived from the Animal Model Mastomys coucha.

Authors:  Daniel Hasche; Sonja Stephan; Larissa Savelyeva; Frank Westermann; Frank Rösl; Sabrina E Vinzón
Journal:  PLoS One       Date:  2016-08-17       Impact factor: 3.240

6.  Development of a Decellularized Porcine Esophageal Matrix for Potential Applications in Cancer Modeling.

Authors:  Hersh Chaitin; Michael L Lu; Michael B Wallace; Yunqing Kang
Journal:  Cells       Date:  2021-04-29       Impact factor: 6.600

7.  A patient derived xenograft model of cervical cancer and cervical dysplasia.

Authors:  Luke I Larmour; Fiona L Cousins; Julie A Teague; James A Deane; Tom W Jobling; Caroline E Gargett
Journal:  PLoS One       Date:  2018-10-26       Impact factor: 3.240

Review 8.  Phthalocyanine and Its Formulations: A Promising Photosensitizer for Cervical Cancer Phototherapy.

Authors:  Lucimara R Carobeli; Lyvia E de F Meirelles; Gabrielle M Z F Damke; Edilson Damke; Maria V F de Souza; Natália L Mari; Kayane H Mashiba; Cristiane S Shinobu-Mesquita; Raquel P Souza; Vânia R S da Silva; Renato S Gonçalves; Wilker Caetano; Márcia E L Consolaro
Journal:  Pharmaceutics       Date:  2021-12-02       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.